SCHEMBL1639477

SCHEMBL1639477

O=C(N/N=C\c1c(O)ccc2ccccc12)c1ccc(O)cc1O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RRM1 P23921 6/20 0.77
MEN1 O00255 7/20 0.72
KMT2A Q03164 7/20 0.72
NPC1 O15118 5/20 0.72
RAB9A P51151 5/20 0.67
GCGR P47871 1/20 0.67
IDO1 P14902 2/20 0.65
PPARG P37231 1/20 0.63
PAX8 Q06710 1/20 0.62
KLF5 Q13887 3/20 0.58
POLB P06746 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
HSP90AA1 P07900 2/20 0.58
KDM4E B2RXH2 1/20 0.58
LMNA P02545 1/20 0.58
GAA P10253 1/20 0.58
MAPT P10636 1/20 0.58
HPGD P15428 1/20 0.58
ALOX12 P18054 1/20 0.58
PTBP1 P26599 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639479 1.00 RRM1 (0.77) RRM1MEN1KMT2ANPC1RAB9A
SCHEMBL12766750 1.00 RRM1 (0.77) RRM1MEN1KMT2ANPC1RAB9A
SCHEMBL29366011 0.87 RRM1 (1.00) RRM1MEN1KMT2ANPC1RAB9A
SCHEMBL1637574 0.87 RRM1 (1.00) RRM1MEN1KMT2ANPC1RAB9A
SCHEMBL4454258 0.87 RRM1 (1.00) RRM1MEN1KMT2ANPC1RAB9A
SCHEMBL1637575 0.87 RRM1 (1.00) RRM1MEN1KMT2ANPC1RAB9A
SCHEMBL22245273 0.84 GCGR (0.76) MEN1KMT2ANPC1RAB9AGCGR
SCHEMBL20115427 0.84 GCGR (0.76) MEN1KMT2ANPC1RAB9AGCGR
SCHEMBL16035633 0.84 MEN1 (0.81) RRM1MEN1KMT2ANPC1RAB9A
SCHEMBL14906922 0.84 MEN1 (0.81) RRM1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 RRM1 3099/4885MEN1 2974/4885KMT2A 3625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.